| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | Halozyme Therapeutics, Inc. | Sep 29, 2026 | |
| Buy | Halozyme Therapeutics, Inc. | Mar 9, 2026 | |
| Sell | HALOZYME THERAPEUTICS INC CM | Feb 1, 2026 | |
| Sell | Halozyme Therapeutics, Inc. | Mar 24, 2025 | |
| Sell | Halozyme Therapeutics, Inc. | Sep 9, 2024 | |
| Sell | Daniel Goldman Grandchildren | Jul 12, 2023 | |
| Sell | Halozyme Therapeutics, Inc. | Jul 12, 2023 | |
| Sell | Halozyme Therapeutics, Inc. | Dec 6, 2022 | |
| Sell | Halozyme Therapeutics, Inc. | Aug 5, 2022 | |
| Buy | HALOZYME THERAPEUTICS INC CM | Aug 23, 2021 |
This page tracks congressional stock trading activity in Halozyme Therapeutics, Inc. (HALO) in the Healthcare sector. Disclosed Capitol has indexed 14 disclosed congressional trades involving HALO. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of October 2026 — Disclosed Capitol has tracked 14 disclosed congressional trades in Halozyme Therapeutics, Inc. (HALO) — 8:5 sell-heavy ratio — led by Josh Gottheimer (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Sep 29, 2026 | Gilbert Cisneros | D | Sell | $1,001 - $15,000 |
| Mar 9, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Feb 1, 2026 | Ro Khanna | D | Sell | $15,001 - $50,000 |
| Mar 24, 2025 | Gilbert Cisneros | D | Sell | $1,001 - $15,000 |
| Sep 9, 2024 | Josh Gottheimer | D | Sell | $1,001 - $15,000 |
| Jul 12, 2023 | Daniel Goldman | D | Unknown | $15,001 - $50,000 |
| Jul 12, 2023 | Daniel Goldman | D | Sell | $15,001 - $50,000 |
| Dec 6, 2022 | Josh Gottheimer | D | Sell | $1,001 - $15,000 |
| Aug 5, 2022 | Josh Gottheimer | D | Sell | $1,001 - $15,000 |
| Aug 23, 2021 | Ro Khanna | D | Buy | $1,001 - $15,000 |
Across the 14 disclosed congressional trades in Halozyme Therapeutics, Inc. (HALO), members of Congress have reported 5 buys and 8 sells. The average 30-day alpha vs. the S&P 500 is 8.68%.
For fiscal year 2025, Halozyme Therapeutics, Inc. reported revenue of $1.40B and net income of $316.9M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $481.0M, net income $229.9M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.